- Home
- NCV vs PHAT Comparison
NCV vs PHAT Comparison
Compare NCV & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- PHAT
- Stock Information
- Founded
- NCV 2003
- PHAT 2018
- Country
- NCV United States
- PHAT United States
- Employees
- NCV N/A
- PHAT N/A
- Industry
- NCV Finance Companies
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- NCV Finance
- PHAT Health Care
- Exchange
- NCV Nasdaq
- PHAT Nasdaq
- Market Cap
- NCV 305.7M
- PHAT 289.0M
- IPO Year
- NCV N/A
- PHAT 2019
- Fundamental
- Price
- NCV $13.49
- PHAT $4.64
- Analyst Decision
- NCV
- PHAT Strong Buy
- Analyst Count
- NCV 0
- PHAT 4
- Target Price
- NCV N/A
- PHAT $16.25
- AVG Volume (30 Days)
- NCV 405.1K
- PHAT 2.0M
- Earning Date
- NCV 01-01-0001
- PHAT 05-01-2025
- Dividend Yield
- NCV 12.48%
- PHAT N/A
- EPS Growth
- NCV N/A
- PHAT N/A
- EPS
- NCV N/A
- PHAT N/A
- Revenue
- NCV N/A
- PHAT $81,859,000.00
- Revenue This Year
- NCV N/A
- PHAT $195.45
- Revenue Next Year
- NCV N/A
- PHAT $106.76
- P/E Ratio
- NCV N/A
- PHAT N/A
- Revenue Growth
- NCV N/A
- PHAT 3055.70
- 52 Week Low
- NCV $2.84
- PHAT $2.21
- 52 Week High
- NCV $3.59
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- NCV 60.23
- PHAT 60.02
- Support Level
- NCV $13.36
- PHAT $4.05
- Resistance Level
- NCV $13.56
- PHAT $4.35
- Average True Range (ATR)
- NCV 0.19
- PHAT 0.39
- MACD
- NCV -0.01
- PHAT 0.14
- Stochastic Oscillator
- NCV 86.30
- PHAT 97.00
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.